2 followers
Arbutus Biopharma Corporation (NASDAQ:ABUS) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV).
Michael McElhaugh